What happens when you stop taking Ozempic®? There’s no one-size-fits-all answer to this question. When you stop taking ...

Ozempic and Mounjaro are both very popular for weight loss at the minute, but there's one big difference between the two ...

Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Novo Nordisk (NVO 0.46%), a Danish pharmaceutical company, is the developer of Ozempic, which is often referred to as a weight-loss drug.But there is actually a nuance, albeit an important one, to ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

Novo Nordisk trades at a significant discount to Eli Lilly, offering nearly 38% upside. Click here to find out why NVO stock ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

Novo Nordisk’s Wegovy is FDA-approved for weight loss, while its lower-dose GLP-1 cousin Ozempic is only officially approved for Type 2 diabetes but is often prescribed off-label for weight loss.

In what Science magazine has dubbed “Novo Nordisk’s Canadian Mistake,” Ozempic is soon to come off patent in Canada, opening ...

LONDON, May 2 (Reuters) – Novo Nordisk has seen the price of its hugely popular weight-loss drug Wegovy and diabetes drug Ozempic fall in the United States as volumes and competition have ...